Compare LWLG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWLG | IRWD |
|---|---|---|
| Founded | 1991 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.6M | 526.7M |
| IPO Year | 2011 | 2009 |
| Metric | LWLG | IRWD |
|---|---|---|
| Price | $8.15 | $3.42 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.94 |
| AVG Volume (30 Days) | ★ 6.1M | 2.3M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.79 | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | $236,855.00 | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ N/A | $23.53 |
| Revenue Growth | ★ 147.74 | 8.88 |
| 52 Week Low | $0.83 | $0.55 |
| 52 Week High | $9.03 | $5.78 |
| Indicator | LWLG | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 47.75 |
| Support Level | $3.46 | $3.07 |
| Resistance Level | $8.42 | $3.53 |
| Average True Range (ATR) | 0.91 | 0.22 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 70.88 | 43.72 |
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.